Cambridge’s Sage Therapeutics, which is developing a treatment for a life-threatening seizure condition, has filed its intentions to go public.
The filing with US Securities and Exchange Commission shows the company aims to raise up to $69 million in the initial public offering to further develop and commercialize its therapies.
The filing comes three months after the company raised a Series C venture round of $38 million.
Third Rock Ventures, a Boston life science venture firm, founded Sage in 2011.
Sage Theraputics shares plunge after depression drug fails late-stage trial
The firm has raised $93 million in funding to date.
Top shareholders in Sage Therapeutics include Third Rock (58.5 percent of shares), ARCH Venture Partners (21.3 percent of shares), and Fidelity Investments (5.6 percent of shares).
The filing comes as two Boston-area biotech firms, Cambridge-based Zafgen and Waltham-based Syndax Pharmaceuticals, are expected to complete their IPOs.
Sage’s initial treatment is an intravenous medicine for a seizure condition known as super refractory status epilepticus, which strikes 150,000 US patients each year and currently has no approved therapies.
Sage recently opened enrollment for a Phase 1/2 clinical trial of the product candidate, SAGE-547.
The treatment is the lead program in a potential portfolio of seizure medicines, Sage has said.
It will be followed by intravenous and oral compounds designed to treat patients with earlier-stage seizure disorders, along with other central nervous system disorders, the company has said.